Evidence map›Paper›PMID 28453388›Full record

ArticleCell cycle (Georgetown, Tex.)2017

Susceptibility of ATM-deficient pancreatic cancer cells to radiation.

Michael Ayars, James Eshleman, Michael Goggins

Abstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Review
  10. Article
  11. Article
  12. Genes · 2020
    Review
  13. Review
  14. Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael Ayarsa Department of Pathology , The Johns Hopkins University School of Medicine , Baltimore , MD, USA.ORCID http://orcid.org/0000-0002-1300-5383
James Eshlemana Department of Pathology , The Johns Hopkins University School of Medicine , Baltimore , MD, USA.
Michael Gogginsa Department of Pathology , The Johns Hopkins University School of Medicine , Baltimore , MD, USA.

Funding

Using markers to improve pancreatic cancer screening and surveillance: a multi-center studyU01CA210170 · NCI · JOHNS HOPKINS UNIVERSITY · PI Michael G. Goggins · 2016 to 2026
$9.3M
NCI NIH HHS U01 CA210170
6 · The paper itself

Abstract

Ataxia telangiectasia mutated (ATM) is inactivated in a significant minority of pancreatic ductal adenocarcinomas and may be predictor of treatment response. We determined if ATM deficiency renders pancreatic cancer cells more sensitive to fractionated radiation or commonly used chemotherapeutics. ATM expression was knocked down in three pancreatic cancer cell lines using ATM-targeting shRNA. Isogenic cell lines were tested for sensitivity to several chemotherapeutic agents and radiation. DNA repair kinetics were analyzed in irradiated cells using the comet assay. We find that while rendering pancreatic cancer cells ATM-deficient did not significantly change their sensitivity to several chemotherapeutics, it did render them exquisitely sensitized to radiation. Pancreatic cancer ATM status may help predict response to radiotherapy.

Indexed as

AdenocarcinomaAtaxia Telangiectasia Mutated ProteinsCarcinoma, Pancreatic DuctalCell Line, TumorDNA Breaks, Double-StrandedDNA DamageDNA RepairGene Expression Regulation, NeoplasticHumansPhosphorylationRadiation ToleranceAtaxia Telangiectasia Mutated ProteinsATM protein, humanATMpancreatic cancerradiosensitivity

Identifiers

PMID28453388
PMCPMC5462076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.